|Day Low/High||7.62 / 7.80|
|52 Wk Low/High||2.56 / 19.99|
M&A activity should perk up substantially in the small and mid-cap space this year.
If the indices take out yesterday's lows I'll be very bearish very quickly.
This biopharma company's Relistor drug should send revenues sharply higher this year.
I've got my eye on steel and biotechnology names to put cash to work.
This biopharma company's Relistor drug should send revenues sharply higher next year.
Good picks make it easier to produce good results, but they are just a starting point.
What's in, what's out and who should thrive in the new political landscape.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors in Aratana Therapeutics, Inc saw new options begin trading this week, for the January 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PETX options chain for the new January 2017 contracts and identified the following put contract of particular interest.
Veterinary drug play Aratana Therapeutics is among the potential solid performers next year.
The market isn't buying that Trump is bad for business
Such unwarranted fears have depressed the sector, which could bounce back after Nov. 8.
The trading action remains quite tedious, though there are short-term opportunities out there.
If you control your risk, then the returns will come.
Biotechnology stocks can be risky but it's helpful to track them over time.
Breadth is running very poor -- at more than 2 to 1 negative.
Slew of news hasn't created much action.
I'm even staying away from the appealing stocks.
Because every stock has a unique personality that requires its own strategy.
Investors in Aratana Therapeutics, Inc saw new options begin trading this week, for the May 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Instead of celebration of good gains, there is grumbling about not keeping pace with the indices.